Recombinant monoclonal antibody to HAVCR2. Clone F38-2E2 is a mouse IgG1, κ that can be potentially used in the treatment of cancer.
Figure 1 Mixed lymphocyte reaction on day 1 or day 7 following treatment with F38-2E2, mAb15 or an isotype control.
Supernatants were assessed for their expression of IL-1β, TNFα and IFN-γ at the time points indicated.
Figure 2 Expression of GM-CSF (FIG. A) and IL-6 (FIG. B) from activated macrophages from two different donors one day following treatment with anti-TIM-3 antibodies. Controls included F38-2E2, a commercially available anti-TIM-3 antibody and mIgG isotype controls.
Figure 3 PBMC from a donor with low LILRB2 showed diminished modulation of GM-CSF, IL-1β, and TNFα expression with mAb15 compared to F38-2E2.
Donor KP42331 expressed LILRB2 (left panel, top). Donor KP42334 showed low expression of LILRB2 (left panel, bottom). Antibodies were the commercially available anti-TIM-3 antibody F38-2E2 and anti-TIM-3 antibody mAb15. mIgG1 served as an isotype control.
Figure 4 Dose curve of release of IL-1β from macrophages stimulated by LPS following treatment with different doses of antibodies.
Antibodies were the commercially available anti-TIM-3 antibody F38-2E2 (circles), anti-TIM-3 antibody mAb15 (squares) and anti-LILRB2 (clone 287219) (inverted triangles). mIgG1 isotype (diamonds) and no antibody (triangles) served as a negative control. Data were collected at 24 hr, 48 hr, and 3 days post-treatment as indicated.
Figure 5 A graph demonstrating a dose curve of release of IL-1β from macrophages stimulated by LPS following treatment with different doses of antibodies.
Antibodies were the commercially available anti-TIM-3 antibody F38-2E2 (circles), anti-TIM-3 antibody mAb15 (diamonds), and commercially available anti-LILRB2 antibody (clone 287219) (triangles). Data were collected at day 1-post-treatment. Data were normalized.
Figure 6 A graph demonstrating a dose curve of release of TNFα from macrophages stimulated by LPS following treatment with different doses of antibodies.
Antibodies were the commercially available anti-TIM-3 antibody F38-2E2 (circles), anti-TIM-3 antibody mAb15 (diamonds), and commercially available anti-LILRB2 antibody (triangles). Data were collected at day 3 post-treatment. Data were normalized.
Figure 7 A graph demonstrating a dose curve of release of TNFα from macrophages stimulated by HMGB-1 following treatment with different doses of antibodies.
Antibodies were the commercially available anti-TIM-3 antibody F38-2E2 (circles) and anti-TIM-3 antibody mAb15 (squares). Data were normalized.
Figure 8 Graphs demonstrating release of IL-1β (FIGS. A), TNFα (FIGS. B) and IL-6 (FIGS. C) from macrophages stimulated by HMGB-1.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-893CQ | Rat Anti-Havcr2 Recombinant Antibody (clone B8.2C12) | Block, FC | Rat IgG1 |
NEUT-894CQ | Rat Anti-Havcr2 Recombinant Antibody (clone RMT3-23) | Block, FC | Rat IgG2a |
There are currently no Customer reviews or questions for HPAB-0192-LSX. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.